{"name":"GLAXOSMITHKLINE LLC","slug":"glaxosmithkline-llc","ticker":"","exchange":"","domain":"glaxosmithklinellc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Exdensur first approved","drug":"Exdensur","drugSlug":"depemokimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Exdensur","genericName":"DEPEMOKIMAB","slug":"depemokimab","indication":"severe asthma","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EXDENSUR","genericName":"DEPEMOKIMAB-ULAA","slug":"depemokimab-ulaa","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Exdensur","genericName":"DEPEMOKIMAB","slug":"depemokimab","phase":"marketed","mechanism":"Exdensur works by binding to histamine, preventing it from interacting with its receptors and reducing inflammation and airway constriction.","indications":["severe asthma","acute bronchospasm","status asthmaticus"],"catalyst":""},{"name":"EXDENSUR","genericName":"DEPEMOKIMAB-ULAA","slug":"depemokimab-ulaa","phase":"marketed","mechanism":"Depemokimab-ulaa binds to IL-5, blocking its interaction with the IL-5 receptor and reducing eosinophil activity.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}